CLS’ board has extensive experience in the medtech industry and in the commercialization of medtech products, as well as a broad knowledge of oncology, financial markets and economics.
born in 1950
Chairman of the Board since 2013
Education/background: Hans von Celsing, MBA Harvard Business School, was vice president of Elekta (1986-98) and was responsible for major parts of the company’s international marketing efforts, primarily in the US and Asia.
Other assignments: Chairman of the Board of Partner Fondkomission AB, Peptonic Medical AB and ADAM SA. Board member of Advanced Oncotherapy Plc.
Holdings in CLS: 500 class A shares, 26,910 class B shares.
Dependency: Independent in relation to the company and its management, independent of the company’s major shareholders.
born in 1961
Member of the Board since 2021
Education/background: Sandy Brandmeier, MBA, has extensive experience from the medical device industry through leading management positions in GE Healthcare, Instrumentarium and Leica Microsystems. Brandmeier is currently President of Sonova, USA. She has extensive knowledge in the launch and establishment of medical devices, especially in the US market.
Other assignments: No other board assignments.
Holdings in CLS: 1,785 class B shares.
Dependency: Independent in relation to the company and its management, independent of the company’s major shareholders.
born in 1967
Member of the Board since 2020
Education/background: Marika Crohns, MD, PhD and MBA, is Senior Director of the Sanofi Group, responsible for Medical Affairs, Europe, for oncology, hematology, and transplantation of solid organs. Crohns has extensive experience and a wide network of contacts in the field of oncology, both clinically and commercially.
Other assignments: No other board assignments.
Holdings in CLS: 971 class B shares.
Dependency: Independent in relation to the company and its management, independent of the company’s major shareholders.
born in 1949
Member of the board since 2006
Education/background: Lars-Erik Eriksson, MBA, has long experience from the banking industry, with positions as chief auditor for Sparbankerna in Sweden, as well as for national and international companies of Föreningsbanken. CEO of CLS 2006-2020.
Other assignments: Partner in ED-Consult HB, Chairman of the Board of CLAR Wine AB. Board member of Elano AB and Salitre AB.
Holdings in CLS: 1,500 class A shares and 3,502 class B shares via Elano AB.
Dependency: Independent in relation to the company and its management, independent in relation to the company’s major owners.
born in 1965
Member of the Board since 2021
Education / background: Paolo Rafaelli, BSc, MBA, has over 25 years of experience from the medical device industry with international management positions at large American and Swedish companies. In his roles, Raffaelli has commercialized innovative products for minimally invasive therapies in interventional radiology and cardiology. He has also worked with strategic product development.
Other assignments: Board member of Acarix AB 2019-2021.
Holdings in CLS: 100 class B shares.
Dependency: Independent in relation to the company and its management, independent in relation to the company’s major owners.
Last updated on 2024-09-02
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region
